Thinklogical Achieves Prestigious Accreditation for Common Criteria EAL-4 Certification for its line of VX Routers
The VX Series is the only routing solution on the market that complies with NATO Directive AC/322-D(2007)0047 for MULTI-CLASSIFICATION Information Assurance.
Thinklogical, a leading provider of fiber optic routing and extension solutions, today announced that it has received accreditation for Common Criteria Part 3, EAL-4 for their VX320, VX160, and VX40 switches. Thinklogical is the only supplier that has established an Information Assurance (IA) methodology across high-end video switching equipment to meet EAL-4 certification requirements.
Common Criteria is an internationally recognized set of guidelines, which define a common framework for evaluating security features and capabilities of Information Technology products. The standard consists of several predetermined evaluation assurance levels, each one more stringent than the last. Once completed, Common Criteria certifications are accepted by NATO through the Common Criteria Recognition Agreement (CCRA).
The VX Optical Routing solutions support any video format at any resolution, with no frame or pixel loss, as well as any computer or video related peripheral data. When deployed with Thinklogical Velocity Extenders, the resulting system is the only Common Criteria, EAL-4 certified solution providing multi-classification secure computing and video routing within the same chassis.
“The Thinklogical VX family of fiber optic matrix routers is the only solution available on the market that is protocol agnostic, and combines 6.5 Gbps per port performance in a switch platform that can scale to a full 320 x 320 matrix”, said Kevin Keefe, Vice President of Engineering. “Thinklogical’s EAL-4 certification is a significant milestone for the company and establishes a new industry benchmark for secure optical routing solutions.”
Common Criteria EAL-4 accreditation confirms that the unique and proprietary VX technology provides secure data separation in restrictive switching environments where secure access between source and destination end points is critical. This provides the ability to establish “Red/Black” levels of access within a single system, which is critical in complex, multi-layered secure military and government environments. This solution also meets the regulatory and security demands in the Energy and Utilities markets.
For further information on the VX Router Series and the Velocity Extension Systems please refer to the Thinklogical Web site at www.thinklogical.com . For information on Thinklogical’s products which are EAL-4 certified please refer to the Common Criteria website within the “other devices and systems ” category http://www.commoncriteriaportal.org/products/ .
About Thinklogical
Thinklogical is the leading manufacturer and provider of fiber optic KVM/video extension solutions, and fiber matrix routers and switches. Organizations worldwide rely on Thinklogical's products and solutions for optimal performance in secure visual computing environments. Through pioneering next generation fiber optic extension, switching, and server management technologies Thinklogical helps customers reduce cost and simplify the management of complex computing infrastructures. Thinklogical sells directly and through integrator and VAR channels and is privately held and headquartered in Milford, Connecticut.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6716532&lang=en
Contact:
Thinklogical
Cindy Caserta, 203-647-8700
cindyc@thinklogical.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom